Daniel Chancellor
Director, Thought Leadership
Director, Thought Leadership
+11 year(s) experience
Daniel has a decade of experience as an analyst in the biopharma industry, spanning roles in drug discovery, market analysis, competitive intelligence, and strategic consulting. He covers topics such as COVID-19, immuno-oncology, tumour-agnostic drug development, artificial intelligence, and mergers and acquisitions (M&A), and regularly participates in webinars, conferences, and other speaking arrangements.
Daniel is featured across leading publications such as Nature Reviews Drug Discovery, Fortune, Scientific American, Scrip, In Vivo and Vice.
Prior to joining Informa, Daniel worked as a medicinal chemist at the U.K. biotech company Summit Therapeutics and graduated with First Class Honours in Natural Sciences from the University of Bath.
Trialtrove: 医療用医薬品の臨床試験情報データベース
Disruption to clinical trials was a well-documented side effect of the COVID-19 pandemic, with trial sponsors and clinical sites dramatically scaling back activities in line with increased hospital burden, lockdown measures, and reduced patient mobility.
Topic Coronavirus clinical-trials clinical-trials-blog biopharmaceutical
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.
Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...
With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target
Topic biopharmaceutical drug-review
Biomedtracker: 開発中医薬品をFDA承認確率で評価
Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more.
Topic M A
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Scrip: 世界の医療用医薬品＆製薬...
The tumor-agnostic developer’s toolkit
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Pharmaprojects: 医薬品...
In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.
Topic cancer cell-and-gene-therapy
Strategic Transactions
PharmAI – industry is smartening up to the potential of artificial intelligence
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.
Topic Parkinsons disease
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Download your free infographic using the adjacent form. Get to grips with early-phase opportunities in our depression pipeline with our latest infographic.
In Vivo: 医療用医薬品・医療機器...
03 Feb 2020
Scrip: 世界の医療用医薬品＆製薬産...
26 Jan 2016